StoxTorrent Pharmaceuticals vs Zydus Lifesciences: share price & financials comparison
NSE: TORNTPHARM vs ZYDUSLIFE · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Torrent Pharmaceuticals vs Zydus Lifesciences at a glance
Torrent Pharmaceuticals (TORNTPHARM) has a market capitalisation of ₹1,80,671 Cr, against ₹1,19,550 Cr for Zydus Lifesciences (ZYDUSLIFE). Over the past year Torrent Pharmaceuticals has returned +32.0%, compared with +19.4% for Zydus Lifesciences. On valuation, Zydus Lifesciences trades at a lower P/E of 28.6 versus 85.1. Zydus Lifesciences earns a higher return on equity (15.0% vs 11.6%). Torrent Pharmaceuticals comes out ahead on growth and momentum. Zydus Lifesciences comes out ahead on size, valuation, profitability, financial health and technicals. Across the scored metrics below, Torrent Pharmaceuticals leads on 7 and Zydus Lifesciences on 11. On StoxGud's 10-point checklist, Torrent Pharmaceuticals scores 7/10 and Zydus Lifesciences scores 10/10.
| Metric | Torrent Pharmaceuticals | Zydus Lifesciences |
|---|---|---|
| Size | ||
| Market cap | ₹1,80,671 Cr | ₹1,19,550 Cr |
| Revenue (latest FY) | ₹13,980 Cr | ₹27,148 Cr |
| Net profit (latest FY) | ₹2,163 Cr | ₹5,040 Cr |
| Valuation | ||
| P/E | 85.1 | 28.6 |
| P/B | 9.83 | 4.30 |
| Dividend yield | 0.71% | 0.93% |
| Profitability | ||
| Return on equity | 11.6% | 15.0% |
| Net profit margin | 12.2% | 13.8% |
| Operating margin | 33.2% | 27.0% |
| Growth | ||
| Revenue growth (YoY) | +50.8% | +29.2% |
| Net profit growth (YoY) | -9.6% | -26.5% |
| Revenue CAGR (multi-year) | +11.8% | +12.4% |
| Financial health | ||
| Debt to equity | 0.76 | 0.48 |
| Momentum | ||
| 1-month return | +0.7% | +3.9% |
| 1-year return | +32.0% | +19.4% |
| 3-year CAGR | +34.2% | +27.0% |
| 5-year CAGR | +26.8% | +19.4% |
| 10-year CAGR | +21.7% | +12.1% |
| Distance from 52W high | -7.3% | -3.8% |
| Technicals | ||
| RSI (14) | 66 | 67 |
| Price vs 200-day avg | +4.9% | +15.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Torrent Pharmaceuticals | Zydus Lifesciences |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 7/10 | 10/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Torrent Pharmaceuticals or Zydus Lifesciences?
Torrent Pharmaceuticals has a market cap of ₹1,80,671 Cr and Zydus Lifesciences has a market cap of ₹1,19,550 Cr as of 06 Nov 2026.
Which has a lower P/E, Torrent Pharmaceuticals or Zydus Lifesciences?
Zydus Lifesciences has the lower P/E: Torrent Pharmaceuticals trades at 85.1 and Zydus Lifesciences at 28.6.
Which gave better returns in the last year, Torrent Pharmaceuticals or Zydus Lifesciences?
Torrent Pharmaceuticals did better: Torrent Pharmaceuticals returned +32.0% and Zydus Lifesciences returned +19.4% over one year.
Is Torrent Pharmaceuticals or Zydus Lifesciences a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Torrent Pharmaceuticals scores 7/10 and Zydus Lifesciences scores 10/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.